Granted Patent
B2
US 12,233,057 · App. 17/485,581 · Granted Feb 25, 2025
Small molecules for inhibiting chemokine activity and/or cancer cells growth
Inventors:
Amnon Peled (Tel-Aviv, IL); Michal Abraham Karni (Mevasseret Zion, IL); Orly Eizenberg (Rechovot, IL)
Assignee:
AlonBio Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or inhibiting a kinase and/or in treating a disease or disorder associated with an activity of a kinase, such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B D, E, G and R 1 -R 5 are as defined in the specification.
Claims (24)
1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by Formula Ia and/or Ib:
wherein:
A is an alkyl being at least 4 carbon atoms in length;
B is selected from hydroxy and alkoxy;
D, E and G are each independently selected from hydrogen, hydroxy, alkoxy and alkyl, provided that (i) no more than one of D, E and G is said alkyl, (ii) at least one and no more than two of D, E and G are said alkoxy, and (iii) if two of D, E and G are said alkoxy, none of D, E and G is said alkyl;
R 1 is selected from hydrogen and alkyl; and
each of R 2 -R 5 is independently selected from hydrogen, hydroxy, halo, alkoxy, thioalkoxy, thiol, thioalkoxy and amine.
2. The method of claim 1 , wherein B is alkoxy.
3. The method of claim 1 , wherein E is alkoxy.
4. The method of claim 2 , wherein E is alkoxy.
5. The method of claim 1 , wherein D is alkoxy.
6. The method of claim 1 , wherein G is alkoxy.
7. The method of claim 1 , wherein G is hydrogen.
8. The method of claim 1 , wherein B is alkoxy, E is alkoxy and G is alkoxy or hydrogen.
9. The method of claim 8 , wherein D is alkoxy.
10. The method of claim 1 , wherein D is said alkyl.
11. The method of claim 10 , wherein G is hydrogen.
12. The method of claim 11 , wherein B is alkoxy.
13. The method of claim 11 , wherein B is alkoxy and E is alkoxy.
14. The method of claim 1 , wherein when one of D, E and G is alkyl, said alkyl is at least 4 carbon atoms in length.
15. The method of claim 1 , wherein the compound is selected from:
16. The method claim 1 , wherein the cancer is selected from a leukemia, a melanoma, a lung cancer, a lymphoma, a myeloma, an ovarian cancer, a brain cancer and prostate cancer.
17. The method of claim 1 , wherein said cancer is characterized by expression of CXCR4.
18. The method of claim 1 , further comprising administering to the subject an additional anti-cancer agent.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 31, 2022
From: BIOKINE THERAPEUTICS LTD.
To: ALONBIO LTD.
Reel/Frame 060219/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 10, 2021
From: PELED, AMNON; ABRAHAM KARNI, MICHAL; EIZENBERG, ORLY
To: BIOKINE THERAPEUTICS LTD.
Reel/Frame 058067/0751 →
Continuity (3)
Division
16063279
Provisional Application
62268586
· Dec 17, 2015
References Cited (190)
US 5116964A
· Capon et al.
· 1992
[cited by applicant]
US 5378694A
· Afonso et al.
· 1995
[cited by applicant]
US 5541196A
· Fournet et al.
· 1996
[cited by applicant]
US 6002008A
· Wissner et al.
· 1999
[cited by applicant]
US 9493557B2
· Abraham et al.
· 2016
[cited by applicant]
US 20080299130A1
· Ambati
· 2008
[cited by applicant]
US 20110027643A1
· Li et al.
· 2011
[cited by applicant]
US 20170015708A1
· Abraham et al.
· 2017
[cited by applicant]
US 20170226157A1
· Peled
· 2017
[cited by applicant]
US 20210228535A1
· Peled et al.
· 2021
[cited by applicant]
CA 3008107
· 2017
[cited by applicant]
EA 003933
· 2003
[cited by applicant]
HU 9903186
· 1999
[cited by applicant]
IN 2003
· 2005
[cited by applicant]
JP 04178647
· 1992
[cited by applicant]
JP H08268881
· 1996
[cited by applicant]
JP 2003512011
· 2003
[cited by applicant]
JP 2003530318
· 2003
[cited by applicant]
JP 2018531613
· 2018
[cited by applicant]
JP 2019502699
· 2019
[cited by applicant]
JP 6941611
· 2021
[cited by applicant]
WO WO9220642
· 1992
[cited by applicant]
WO WO9515758
· 1995
[cited by applicant]
WO WO9521613
· 1995
[cited by applicant]
WO WO9730035
· 1997
[cited by applicant]
WO WO9961428
· 1999
[cited by applicant]
WO WO0010981
· 2000
[cited by applicant]
WO WO0024782
· 2000
[cited by applicant]
WO WO0056720
· 2000
[cited by applicant]
WO WO0121598
· 2001
[cited by applicant]
WO WO0242248
· 2002
[cited by applicant]
WO WO03072599
· 2003
[cited by applicant]
WO WO2007052173
· 2007
[cited by applicant]
WO WO2007094005
· 2007
[cited by applicant]
WO WO2008115870
· 2008
[cited by applicant]
WO WO2010143168
· 2010
[cited by applicant]
WO WO2010146584
· 2010
[cited by applicant]
WO WO2016092544
· 2016
[cited by applicant]
WO WO2017103931
· 2017
[cited by applicant]
WO WO2017103932
· 2017
[cited by applicant]
WO WO2020230144
· 2020
[cited by applicant]
WO WO2020230144A8
· 2021
[cited by applicant]
Notice of Allowance Dated Oct. 20, 2021 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/988,765. (42 pages).
[cited by applicant]
Notice of Allowance Dated May 26, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/585,624. (5 pages).
[cited by applicant]
International Preliminary Report on Patentability Dated Nov. 25, 2021 From the International Bureau of WIPO Re. Application No. PCT/IL2020/050535. (7 Pages).
[cited by applicant]
Examination Report Dated May 27, 2022 From the Instituto Mexicano de la Propiedad Industrial, Direccion Divisional de Patentes Re. Application No. MX/a/2020/011500 and Its Translation Into English. (8 Pages).
[cited by applicant]
Requisition by the Examiner Dated Mar. 21, 2022 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 3,008,107 with Claims. (11 Pages).
[cited by applicant]
Requisition by the Examiner Dated Mar. 28, 2022 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 3,090,315 wit Claims. (9Pages).
[cited by applicant]
Office Action Dated Dec. 8, 2022 From the Israel Patent Office Re. Application No. 288144. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated May 2, 2022 From the European Patent Office Re. Application No. 20185763.8. (3 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated May 3, 2023 From the European Patent Office Re. Application No. 20754606.0. (4 Pages).
[cited by applicant]
Relatório de Exame Tecnico [Technical Examination Report] Dated Feb. 24, 2023 From the Serviço Público Federal, Ministério da Economia, Instituto Nacional da Propriedade Industrial do Brasil Re. Application No. BR 11 20…
[cited by applicant]
Official Action Dated Feb. 2, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/585,624. (63 pages).
[cited by applicant]
Requisition by the Examiner Dated Oct. 4, 2021 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 3,008,107. (3 Pages).
[cited by applicant]
Requisition by the Examiner Dated Oct. 5, 2021 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 3,090,315. (4 Pages).
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Sep. 21, 2021 From the European Patent Office Re. Application No. 20754606.0. (9 Pages).
[cited by applicant]
Official Action Dated Oct. 28, 2022 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/214,993. (56 pages).
[cited by applicant]
Requisition by the Examiner Dated Oct. 21, 2022 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 3,090,315 with Claims. (9 Pages).
[cited by applicant]
Advisory Action Before the Filing of An Appeal Brief Dated Sep. 23, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/378,063.
[cited by applicant]
Communication Pursuant to Article 94(3) Dated Sep. 4, 2020 From the European Patent Office Re. Application No. 16875066.9. (6 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Jun. 3, 2019 From the European Patent Office Re. Application No. 16875067.7. (3 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Aug. 4, 2021 From the European Patent Office Re. Application No. 20185763.8. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated May 7, 2014 From the European Patent Office Re. Application No. 10735337.7.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Dec. 14, 2012 From the European Patent Office Re. Application No. 10735337.7.
[cited by applicant]
Communication Relating to the Results of the Partial International Search Dated Feb. 26, 2017 From the International Searching Authority Re. Application No. PCT/IL2016/051346. (20 Pages).
[cited by applicant]
European Search Report and the European Search Opinion Dated Aug. 21, 2020 From the European Patent Office Re. Application No. 20185763.8. (7 Pages).
[cited by applicant]
Examination Report Dated Jan. 11, 2021 From the Servico Publico Federal, Ministerio da Economia, Instituto Nacional da Propriedade Industrial do Brasil RE Application No. BR1120180123064 and Its Translationsh into Engli…
[cited by applicant]
Examination Report Dated Aug. 13, 2020 From the Instituto Mexicano de la Propiedad Industrial, IMPI, Secretario de Economia, Direccion Divisional de Patentes Re. Application No. MX/a/2018/007361. (3 Pages).
[cited by applicant]
Examination Report Dated Feb. 18, 2014 From the Instituto Mexicano de la Propiedad Industrial Re. Application No. MX/a/2011/013457 and Its Translation Into English.
[cited by applicant]
Examination Report Dated Aug. 19, 2019 From the Australian Government, IP Australia Re. Application No. 2016371466. (2 Pages).
[cited by applicant]
Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 Dated Apr. 26, 2020 From the Government of India, Intellectual Property India, Patents, Designs, Trade Marks, Geographical I…
[cited by applicant]
International Preliminary Report on Patentability Dated Jun. 22, 2017 From the International Bureau of WIPO Re. Application No. PCT/IL2015/051190. (8 Pages).
[cited by applicant]
International Preliminary Report on Patentability Dated Jun. 28, 2018 From the International Bureau of WIPO Re. Application No. PCT/IL2016/051346. (11 Pages).
[cited by applicant]
International Preliminary Report on Patentability Dated Jun. 28, 2018 From the International Bureau of WIPO Re. Application No. PCT/IL2016/051347. (7 Pages).
[cited by applicant]
International Preliminary Report on Patentability Dated Dec. 29, 2011 From the International Bureau of WIPO Re. Application No. PCT/IL2010/000473.
[cited by applicant]
International Search Report and the Written Opinion Dated Mar. 19, 2017 From the International Searching Authority Re. Application No. PCT/IL2016/051347. (10 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Oct. 22, 2010 From the International Searching Authority Re. Application No. PCT/IL2010/000473.
[cited by applicant]
International Search Report and the Written Opinion Dated Mar. 28, 2016 From the International Searching Authority Re. Application No. PCT/IL2015/051190.
[cited by applicant]
International Search Report and the Written Opinion Dated Mar. 29, 2017 From the International Searching Authority Re. Application No. PCT/IL2016/051346. (33 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Jul. 30, 2020 From the International Searching Authority Re. Application No. PCT/IL2020/050535. (11 Pages).
[cited by applicant]
Notice of Allowance Dated Jul. 1, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/178,301.
[cited by applicant]
Notice of Allowance Dated Jan. 16, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/063,278. (9 pages).
[cited by applicant]
Notice of Allowance Dated Nov. 16, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/868,558. (31 pages).
[cited by applicant]
Notice of Allowance Dated May 26, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/063,279. (9 Pages).
[cited by applicant]
Notice of Allowance Dated Oct. 29, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/378,063.
[cited by applicant]
Notice of Preliminary Rejection Dated Feb. 8, 2017 From the Korean Intellectual Property Office Re. Application No. 2012-7000920. (6 Pages).
[cited by applicant]
Notice of Reason for Rejection Dated Dec. 8, 2020 From the Japan Patent Office Re. Application No. 2018-531613. and Its Translation Into English. (5 Pages).
[cited by applicant]
Notice of Reason for Rejection Dated Oct. 17, 2014 From the Japanese Patent Office Re. Application No. 2012-515627 and Its Translation Into English.
[cited by applicant]
Notification of Office Action and Search Report Dated Nov. 20, 2020 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201680081132.9 and Its Translation of Office Action I…
[cited by applicant]
Notification of Office Action Dated Oct. 31, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201080036127.9 and Its Translation Into English.
[cited by applicant]
Office Action Dated Jul. 8, 2013 From the Israel Patent Office Re. Application No. 216978 and Its Translation Into English.
[cited by applicant]
Office Action Dated Jun. 11, 2020 From the Israel Patent Office Re. Application No. 260081 and Its Translation Into English. (5 Pages).
[cited by applicant]
Office Action Dated Mar. 11, 2021 From the Israel Patent Office Re. Application No. 277261 and Its Translation Into English. (5 Pages).
[cited by applicant]
Office Action Dated Nov. 17, 2019 From the Israel Patent Office Re. Application No. 260082 and Its Translation Into English. (7 Pages).
[cited by applicant]
Office Action Dated Mar. 26, 2015 From the Israel Patent Office Re. Application No. 216978 and Its Translation Into English.
[cited by applicant]
Official Action Dated Jul. 1, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/378,063.
[cited by applicant]
Official Action Dated Feb. 5, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/063,279. (60 Pages).
[cited by applicant]
Official Action Dated Jul. 7, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/178,301.
[cited by applicant]
Official Action Dated Jan. 8, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/378,063.
[cited by applicant]
Official Action Dated Feb. 9, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/178,301.
[cited by applicant]
Official Action Dated Jun. 15, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/868,558. (9 pages).
[cited by applicant]
Official Action Dated Sep. 20, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/063,278. (25 pages).
[cited by applicant]
Official Action Dated Aug. 21, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/326,512. (42 pages).
[cited by applicant]
Official Action Dated Aug. 28, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/285,492. (31 pages).
[cited by applicant]
Patent Examination Report Dated Aug. 23, 2021 From the Australian Government, IP Australia Re. Application No. 20202004524. (2 Pages).
[cited by applicant]
Request for Examination and Search Report Dated Apr. 3, 2020 From the Federal Government Institution, Federal Institute of Industrial Property of the Federal Service of Intellectual Property, Patents and Trademarks of t…
[cited by applicant]
Request for Examination Dated Oct. 2, 2020 From the (ROSPatent), Federal Government Institution of Industrial Property of the Federal Service of Intellectual Property, Patents and Trademark of the Russian Federation Re.…
[cited by applicant]
Requisition by the Examiner Dated May 25, 2016 From the Canadian Intellectual Property Office Re. Application No. 2,765,188.
[cited by applicant]
Requisition by the Examiner Dated Jun. 27, 2017 From the Canadian Intellectual Property Office Re. Application No. 2,765,188. (8 Pages).
[cited by applicant]
Restriction Official Action Dated Jul. 2, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/063,278. (7 pages).
[cited by applicant]
Restriction Official Action Dated Mar. 10, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/178,301.
[cited by applicant]
Restriction Official Action Dated Nov. 17, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/063,279. (6 Pages).
[cited by applicant]
Restriction Official Action Dated Aug. 23, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/378,063.
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Nov. 7, 2019 From the European Patent Office Re. Application No. 16875066.9. (13 Pages).
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Sep. 19, 2018 From the European Patent Office Re. Application No. 16875067.7. (5 Pages).
[cited by applicant]
Supplementary Partial European Search Report and the European Provisional Opinion Dated Aug. 5, 2019 From the European Patent Office Re. Application No. 16875066.9. (18 Pages).
[cited by applicant]
Translation of Notice of Preliminary Rejection Dated Feb. 8, 2017 From the Korean Intellectual Property Office Re. Application No. 2012-7000920. (4 Pages).
[cited by applicant]
Translation of Office Action Dated May 2, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201080036127.9.
[cited by applicant]
Translation of Search Report May 2, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201080036127.9.
[cited by applicant]
Baggiolini et al. “CC Chemokines in Allergic Inflammation”, Immunology Today, 15(3): 127-133, 1994.
[cited by applicant]
Bork “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”, Genome Research, 10: 398-400, 2000.
[cited by applicant]
Carreras Puigvert et al. “Targeting DNA Repair, DNA Metabolism and Replication Stress as Anti-Cancer Strategies”, The FEBS Journal, XP055607460, 283(2): 232-245, Published Online Oct. 28, 2015.
[cited by applicant]
Cocchi et al. “Identification of Rantes, MIP-1 [Alpha], and MIP-1 [Beta] as the Major HIV-Suppressive Factors Produced by CD8+ T Cells”, Science, 270(5243): 1811-1815, Dec. 15, 1995.
[cited by applicant]
Debnath et al. “Small Molecule Inhibitors of CXCR4”, Theranostics, XP055391478, 3(1): 47-75, Jan. 15, 2013. Abstract, Figs.
[cited by applicant]
Doercks et al. “Protein Annotation: Detective Work for Function Prediction”, Trends in Genetics, TiG, 14(6): 248-250, Jun. 1998.
[cited by applicant]
Duan et al. “Inhaled P38[Alpha] Mitogen-Activated Protein Kinase Antisense Oligonucleotide Attenuates Asthma in Mice”, American Journal of Respiratory and Critical Care Medicine, 171: 571-578, Originally Published Nov. …
[cited by applicant]
Elix et al. “Annelated Furans. XVIII. The Photocyclization of 2-Methoxyphenyl Phenyl Ethers”, Australian Journal of Chemistry, 28(7): 1559-1582, Dec. 31, 1975. p. 1562, Compounds 11, 12, 14.
[cited by applicant]
Epifano et al. “Auraptene and Its Effects on the Re-Emergence of Colon Cancer Stem Cells”, Phytotherapy Research, 27(5): 784-786, Epub Jul. 4, 2012.
[cited by applicant]
Escott et al. “Effect of the P38 Kinase Inhibitor, SB 203580, on Allergic Airway Inflammation in the Rat”, British Journal of Pharmacology, 131(2): 173-176, Sep. 2000.
[cited by applicant]
Haddad et al. “Role of P38 Map Kinase in LPS-Induced Airway Inflammation in the Rat”, British Journal of Pharmacology, 132(8): 1715-1724, Apr. 2001.
[cited by applicant]
Hu et al. “Design, Synthesis, and Biological Evaluation of Novel Quinazoline Derivatives as Anti-Inflammatory Agents Against Lipopolysaccharide-Induced Acute Lung Injury in Rats”, Chemical Biology & Drug Design, 85(6): …
[cited by applicant]
Huang et al. “Anticancer Activities of Polyynes From the Root Bark of Oplopanax Horridus and Their Acetylated Derivatives”, Molecules, 19: 6142-6162, May 14, 2014.
[cited by applicant]
Joulain et al. “Lichen Extracts as Raw Materials in Perfumery. Part 2: Treemoss”, Flavour and Fragrance Journal, 24(3): 105-116, Mar. 11, 2009. p. 5, Fig.4, Compounds 32-33.
[cited by applicant]
Kasuga et al. “Sensitization of Human Glioblastomas to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) by NF-KB Inhibitors”, Cancer Science, 95(10): 840-844, Oct. 2004.
[cited by applicant]
Kim et al. “Isolation and Characterization of Antitumor Agents From Dictamnus Albus”, Saengyak Hakhoe Chi, 28(4): 209-214, Dec. 28, 1997.
[cited by applicant]
Kioi et al. “Inhibition of Vasculogenesis, But Not Angiogenesis, Prevents the Recurrence of Glioblastoma After Irradiation in Mice”, the Journal of Clincal Investigation, 120(3): 694-705, Mar. 2010.
[cited by applicant]
Kryczek et al. “Stroma-Derived Factor (SDF-1/CXCL12) and Human Tumor Pathogenesis”, American Journal of Physioloy, Cell Physiology, 292(3): C987-C995, First Published Aug. 30, 2006.
[cited by applicant]
Lee et al. “Ocular Neovascularization: An Epidemiologic Review”, Survey of Ophthalmology, 43(3): 245-269, Nov.-Dec. 1998.
[cited by applicant]
Lo et al. “High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells”, Protein Engineering, 11(6): 495-500, Jun. 1998.
[cited by applicant]
Luhmann et al. The Relevance of Chemokine Signalling in Modulating Inherited and Age-Related Retinal Degenerations:, Retinal Degenerative Diseases, Chap.54: 427-433, Mar. 25, 2014.
[cited by applicant]
Ma et al. “Impaired B-Lymphopoiesis, Myelopoiesis, and Derailed Cerebellar Neuron Migration in CXCR4- and SDF-1-Deficient Mice”, Proc. Natl. Acad. Sci. USA, 95(16): 9448-9453, Aug. 1998.
[cited by applicant]
Mathebula “A Review of Ocular Genetics and Inherited Eye Diseases”, African Vision and Eye Health, 71(4): 179-189. 2012.
[cited by applicant]
Niu et al. “New Polyphenols From a Deep sea
[cited by applicant]
Nomura et al. “Effects of Oakmoss and Its Components on Biofilm Formation of Legionella Pneumophila”, Biological and Pharmaceutical Bulletin, 36(5): 833-837, May 2013. Compounds 14, 17, 20, p. 834.
[cited by applicant]
Nomura et al. “The Antibacterial Activity of Compounds Isolated From Oakmoss Against Legionella Pneumophila and Other
[cited by applicant]
Reeck et al. “‘Homology’ in Proteins and Nucleic Acids: A Terminology Muddle and a Way Out of It”, Cell, 50(5): 667, Aug. 28, 1987.
[cited by applicant]
Rutar et al. “Small Interfering RNA-Mediated Suppression of Ccl2 in Mueller Cells Attenuates Microglial Recruitment and Photoreceptor Death Following Retinal Degeneration”, Journal of Neuroinflammation, 9(221): 1-15, Pu…
[cited by applicant]
Sechi et al. “Design and Synthesis of Novel Dihydroquinoline-3-Carboxylic Acids as HIV-1 Integrase Inhibitors”, Bioorganic & Medicinal Chemistry, 17(7): 2925-2935, Available Online Nov. 6, 2008.
[cited by applicant]
Skolnick et al. “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era”, Trends in Biotechnology, TiBTech, 18(1): 34-39, Jan. 2000.
[cited by applicant]
Smith et al. “CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer”, Cancer Research, 64: 8604-8612, Dec. 1, 2004.
[cited by applicant]
Stedman “Allograft Rejection”, Stedman's Online, Lippincott Williams and Wilkins, Jun. 23, 2015.
[cited by applicant]
Stedman “Malignant”, Stedman's Online, Lippincott Williams and Wilkins, Jun. 23, 2015.
[cited by applicant]
Stedman “Myasthenia Gravis”, Stedman's Online, Lippincott Williams and Wilkins, Jun. 23, 2015.
[cited by applicant]
Stedman “Systemic Lupus Erythematosus” Stedman's Online, Lippincott Williams and Wilkins, Jun. 23, 2015.
[cited by applicant]
Strieter et al. “The Functional Role of the ELR Motif in CXC Chemokine-Mediated Angiogenesis”, The Journal of Biological Chemistry, 270(45): 27348-27357, Nov. 10, 1995.
[cited by applicant]
Sulaiman et al. “In Vitro and In Silico Studies of Lunacridine From Lunasia Amara Blanco as Anticancer”, Journal of Life Sciences, 5(8): 639-645, Published Online Aug. 30, 2011. Abstract.
[cited by applicant]
Tannock et al. “The Basic Science of Oncology”, Third Edition, New York: McGraw-Hill; p. 357-358, 1998.
[cited by applicant]
Tokuriki et al. “Stability Effects of Mutations and Protein Evolvability”, Current Opinion in Structural Biology, 19: 596-604, 2009.
[cited by applicant]
Toyooka et al. “CD28 Co-Stimulatory Signals Induce IL-2 Receptor Expression on antigen-Stimulated Virgin T Cells by an IL-2-Independent Mechanism”, International Immunology, 8(2): 159-169, Feb. 1996.
[cited by applicant]
Underwood et al. “SB 239063, A P38 MAPK Inhibitor, Reduces Neutrophilia, Inflammatory Cytokines, MMP-9, and Fibrosis in Lung”, American Journal of Physiology, Lung Cellular and Molecular Physiology, 279(5): L895-L902, N…
[cited by applicant]
Underwood et al. “SB 239063, A Potent P38 Map Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence”, The Journal of Pharmacology and Experimental Therapeutics, 293…
[cited by applicant]
Vaddi et al. “Regulation of Monocyte Integrin Expression by Beta-Family Chemokines”, The Journal of Immunology, 153(10): 4721-4732, Nov. 15, 1994.
[cited by applicant]
Wallace et al. “The Role of Chemokines and Their Receptors in Ocular Disease”, Progress in Retinal and Eye Research, 23(4): 435-448, Jul. 2004. p. 446, Pont No. 10.
[cited by applicant]
Wang et al. “Identification of Potential Anticancer Compounds From Oplopanax Horridus”, Phytomedicine, 20(11): 999-1006, Aug. 15, 2013.
[cited by applicant]
Wells “Additivity of Mutational Effects in Proteins”, Biochemistry, 29(37): 8509-8517, Sep. 18, 1990.
[cited by applicant]
Williams et al. “Depsides Isolated From the Sri Lankan Lichen
[cited by applicant]
Wilson et al. “CXCR4 Signaling Mediates Morphine-Induced Tactile Hyperalgesia”, Brain, Behavior, and Immunity, 25(3): 565-573, Epub Dec. 28, 2010.
[cited by applicant]
Zheng et al. “Migration of Endothelial Progenitor Cells Mediated by Stromal Cell-Derived Factor-1 [Alpha]/CXCR4 via P13K/Akt/eNOS Signal Transduction Pathway”, Journal of Cardiovascular Pharmacology, 50(3): 274-280, Sep…
[cited by applicant]
Request for Examination Dated Aug. 25, 2023 From the Federal Government Institution, Federal Institute of Industrial Property of the Federal Service of Intellectual Property, Patents and Trademarks of the Russian Federa…
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Dec. 19, 2023 From the European Patent Office Re. Application No. 20754606.0 (3 Pages).
[cited by applicant]
Translation Dated Sep. 18, 2023 Request for Examination Dated Aug. 25, 2023 From the Federal Government Institution, Federal Institute of Industrial Property of the Federal Service of Intellectual Property, Patents and …
[cited by applicant]
Grounds of Reason of Rejection Dated Mar. 25, 2024 From the Korean Intellectual Property Office Re. Application No. 10-2018-7020455. (5 Pages).
[cited by applicant]
Notice of Reason(s) for Rejection Dated Apr. 30, 2024 From the Japan Patent Office Re. Application No. 2021-568695 and Its Translation Into English. (7 Pages).
[cited by applicant]
Notification of Office Action and Search Report Dated Mar. 29, 2024 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. 202080050533.4. (6 Pages).
[cited by applicant]
Office Action Dated Apr. 7, 2024 From the Israel Patent Office Re Application No. 307561. (4 Pages).
[cited by applicant]
Translation Dated Apr. 9, 2024 of Grounds of Reason of Rejection Dated Mar. 25, 2024 From the Korean Intellectual Property Office Re. Application No. 10-2018-7020455. (3 Pages).
[cited by applicant]
Translation Dated Apr. 12, 2024 of Notification of Office Action Dated Mar. 29, 2024 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. 202080050533.4. (6 Pages).
[cited by applicant]
Examination Report Dated Jul. 8, 2024 From the Instituto Mexicano de la Propiedad Industrial, Secretaria de Economia, Direccion Divisional de Patentes Re. Application No. MX/a/2021/014008 and Its Translation Into Englis…
[cited by applicant]
Notice of Allowance Dated Sep. 10, 2024 together with Interview Summary Dated Sep. 4, 2024 From the US Patent and Trademark Office Re. U.S. Appl. No. 18/369,857. (48 pages).
[cited by applicant]